MMV390048的1期安慰剂对照单次递增剂量及志愿者感染研究:安全性、药代动力学与抗疟活性
MMV390048是首个进入临床研发的疟原虫磷脂酰肌醇4-激酶抑制剂。本研究为2部分1期试验:第1部分为双盲、随机、安慰剂对照的单次递增剂量研究(3个队列:40、80、120 mg),第2部分为开放标签志愿者感染研究(恶性疟原虫诱导血阶段疟疾模型,2个队列:40 mg和80 mg)。结果显示无严重或重度不良事件归因于MMV390048;药代/药效模型估计最低抑菌浓度83 ng/mL、达到90%最大效应的最小杀虫浓度238 ng/mL,预测单次120 mg剂量以92%的确定性实现充分的临床和寄生虫学应答。结论支持其作为单剂量联合疗法伙伴药物的进一步开发。
要点
- MMV390048总体安全,无严重或重度不良事件归因于药物。
- 模型预测单次120 mg剂量以92%确定性实现充分临床和寄生虫学应答。
核心结论
- MMV390048的安全性、药代动力学和药效学支持其作为疟疾单剂量联合疗法的伙伴药物进一步开发。
研究设计与样本
- 2部分1期试验在健康成人中开展。
- 第1部分为双盲、随机、安慰剂对照的单次递增剂量研究,3个队列(40、80、120 mg MMV390048),每队列8例,按3:1随机分配MMV390048:安慰剂。
- 第2部分为开放标签志愿者感染研究,采用恶性疟原虫诱导血阶段疟疾模型,2个队列(40 mg组n=7,80 mg组n=8)。
- 第2部分80 mg队列中1例在给药前退出,未纳入分析。
主要发现
- 未发生归因于MMV390048的严重或重度不良事件。
- 药代/药效模型估计最低抑菌浓度为83 ng/mL,达到90%最大效应的最小杀虫浓度为238 ng/mL。
- 模型预测单次120 mg剂量以92%的确定性实现充分的临床和寄生虫学应答。
关键数值与推荐
- 第1部分单次递增剂量:40、80、120 mg MMV390048。
- 第2部分志愿者感染研究剂量:40 mg和80 mg MMV390048。
- 最低抑菌浓度83 ng/mL;达到90%最大效应的最小杀虫浓度238 ng/mL。
- 预测单次120 mg剂量实现充分应答的确定性为92%。
临床怎么用
- MMV390048作为单剂量联合疗法的伙伴药物具有进一步开发价值。
- 80 mg剂量下观察到更快的寄生虫清除,支持剂量优化探索。
- 模型预测120 mg单次剂量可能达到充分临床和寄生虫学应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial. We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet formulation of MMV390048. METHODS: A 2-part, phase 1 trial was conducted in healthy adults. Part 1 was a double-blind, randomized, placebo-controlled, single ascending dose study consisting of 3 cohorts (40, 80, 120 mg MMV390048). Part 2 was an open-label volunteer infection study using the Plasmodium falciparum induced blood-stage malaria model consisting of 2 cohorts (40 mg and 80 mg MMV390048). RESULTS: Twenty four subjects were enrolled in part 1 (n = 8 per cohort, randomized 3:1 MMV390048:placebo) and 15 subjects were enrolled in part 2 (40 mg [n = 7] and 80 mg [n = 8] cohorts). One subject was withdrawn from part 2 (80 mg cohort) before dosing and was not included in analyses. No serious or severe adverse events were attributed to MMV390048. The rate of parasite clearance was greater in subjects administered 80 mg compared to those administered 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2-6.0 hours] vs 6.4 hours [95% CI, 6.0-6.9 hours]; P = .005). Pharmacokinetic/pharmacodynamic modeling estimated a minimum inhibitory concentration of 83 ng/mL and a minimal parasiticidal concentration that would achieve 90% of the maximum effect of 238 ng/mL, and predicted that a single 120-mg dose would achieve an adequate clinical and parasitological response with 92% certainty. CONCLUSIONS: The safety, pharmacokinetics, and pharmacodynamics of MMV390048 support its further development as a partner drug of a single-dose combination therapy for malaria. CLINICAL TRIALS REGISTRATION: NCT02783820 (part 1); NCT02783833 (part 2).
引用
- McCarthy JS, Donini C, Chalon S, et al. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048. Clin Infect Dis. 2020. PMID: 32239164. doi:10.1093/cid/ciaa368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。